Literature DB >> 21246178

[The various forms of left ventricular hypertrophy: diagnostic value of echocardiography].

F Weidemann1, S Störk, S Herrmann, G Ertl, M Niemann.   

Abstract

Left ventricular hypertrophy is a non-specific physiological or maladaptive cardiac response to a large array of stimuli mediated by exercise and numerous cardiac and systemic diseases. The precise characterization and quantification of left ventricular hypertrophy may allow a more timely diagnosis of the underlying condition. The clinical reference standard to assess left ventricular hypertrophy is echocardiography, but a comprehensive description of how to approach this frequent finding in clinical practice is lacking. The current review systematically describes the typical echocardiographic patterns of important types of cardiac hypertrophy using both established and advanced imaging modalities. In hypertrophic obstructive cardiomyopathy a markedly reduced regional systolic function is found in the prominent thickened septum, whereas in essential arterial hypertension a typical concentric left ventricular hypertrophy with a less prominent basal septal bulge is present. The echocardiographic characteristics of cardiac amyloidosis are ventricular hypertrophy with sparkling granular myocardial texture and a small epicardial effusion. In addition, the strain rate curve for longitudinal function shows a typically reduced function which reaches maximum already in early systole. The typical feature of Friedreich cardiomyopathy is concentric left ventricular hypertrophy and sparkling granular texture with preserved regional systolic function. In Fabry cardiomyopathy a prominent papillary muscle is presented and a typical strain rate curve can be extracted from the basal lateral wall, indicating replacement fibrosis. Prominent hypertrabecularisation (ratio of non-compacted to compacted myocardium >2) in the apical and mid left ventricular segments is typical for non-compaction cardiomyopathy. Knowledge of these typical echocardiographic features enables the cardiologist to distinguish between the different hypertrophic entities, thus paving the way to early diagnosis.

Entities:  

Mesh:

Year:  2011        PMID: 21246178     DOI: 10.1007/s00059-010-3416-1

Source DB:  PubMed          Journal:  Herz        ISSN: 0340-9937            Impact factor:   1.443


  66 in total

1.  Prevalence of left ventricular hypertrophy in a general population; The Tromsø Study.

Authors:  H Schirmer; P Lunde; K Rasmussen
Journal:  Eur Heart J       Date:  1999-03       Impact factor: 29.983

2.  Left ventricular systolic dysfunction during exercise and dobutamine stress in patients with hypertrophic cardiomyopathy.

Authors:  K Okeie; M Shimizu; H Yoshio; H Ino; M Yamaguchi; T Matsuyama; T Yasuda; J Taki; H Mabuchi
Journal:  J Am Coll Cardiol       Date:  2000-09       Impact factor: 24.094

3.  An atypical variant of Fabry's disease in men with left ventricular hypertrophy.

Authors:  S Nakao; T Takenaka; M Maeda; C Kodama; A Tanaka; M Tahara; A Yoshida; M Kuriyama; H Hayashibe; H Sakuraba
Journal:  N Engl J Med       Date:  1995-08-03       Impact factor: 91.245

4.  Abnormally thickened papillary muscle resulting in dynamic left ventricular outflow tract obstruction: an unusual presentation of hypertrophic cardiomyopathy.

Authors:  Bethany A Austin; Deborah H Kwon; Nicholas G Smedira; Maran Thamilarasan; Harry M Lever; Milind Y Desai
Journal:  J Am Soc Echocardiogr       Date:  2009-01       Impact factor: 5.251

Review 5.  Distinguishing hypertrophic cardiomyopathy from athlete's heart physiological remodelling: clinical significance, diagnostic strategies and implications for preparticipation screening.

Authors:  B J Maron
Journal:  Br J Sports Med       Date:  2009-09       Impact factor: 13.800

Review 6.  Hypertrophic cardiomyopathy.

Authors:  Perry Elliott; William J McKenna
Journal:  Lancet       Date:  2004-06-05       Impact factor: 79.321

7.  Epidemiology of idiopathic dilated and hypertrophic cardiomyopathy. A population-based study in Olmsted County, Minnesota, 1975-1984.

Authors:  M B Codd; D D Sugrue; B J Gersh; L J Melton
Journal:  Circulation       Date:  1989-09       Impact factor: 29.690

8.  Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey.

Authors:  A Mehta; R Ricci; U Widmer; F Dehout; A Garcia de Lorenzo; C Kampmann; A Linhart; G Sunder-Plassmann; M Ries; M Beck
Journal:  Eur J Clin Invest       Date:  2004-03       Impact factor: 4.686

9.  Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment.

Authors:  Frank Weidemann; Markus Niemann; Frank Breunig; Sebastian Herrmann; Meinrad Beer; Stefan Störk; Wolfram Voelker; Georg Ertl; Christoph Wanner; Jörg Strotmann
Journal:  Circulation       Date:  2009-01-19       Impact factor: 29.690

10.  Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium.

Authors:  James C C Moon; Bhavesh Sachdev; Andrew G Elkington; William J McKenna; Atul Mehta; Dudley J Pennell; Philip J Leed; Perry M Elliott
Journal:  Eur Heart J       Date:  2003-12       Impact factor: 29.983

View more
  2 in total

Review 1.  [Echocardiography in diabetic cardiomyopathy].

Authors:  M Niemann; S Herrmann; G Ertl; F Weidemann
Journal:  Herz       Date:  2012-11-29       Impact factor: 1.443

Review 2.  Strain Echocardiography and Myocardial Mechanics: From Basics to Clinical Applications.

Authors:  Giovanni Di Salvo; Valeria Pergola; Bahaa Fadel; Ziad Al Bulbul; Pio Caso
Journal:  J Cardiovasc Echogr       Date:  2015 Jan-Mar
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.